• Onco-Innovations agreed to terminate its performance-based funding arrangement with Sorbie, with 5,380,683 common shares to be returned for cancellation.
• Sorbie Bornholm will return 2,761,635 common shares; Sorbie Investments will return 2,619,048 common shares.
• Sorbie Bornholm will receive remaining credit support of CAD 4.44 million; the company will relinquish rights to further payments on that amount.
• Sorbie Investments will irrevocably waive its entitlement to 2,250,000 additional common share purchase warrants, eliminating the company's obligation to issue them.
• The credit-support transfer requires no additional company cash payment; termination remains subject to conditions, including Cboe Canada approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611102324PRIMZONEFULLFEED9875234) on November 11, 2026, and is solely responsible for the information contained therein.